Status:
COMPLETED
Effects of Isoflavone in Patients With Watchful Waiting Benign Prostate Hyperplasia
Lead Sponsor:
Chinese University of Hong Kong
Collaborating Sponsors:
School of Pharmacy, CUHK
Conditions:
Benign Prostate Hyperplasia
Eligibility:
MALE
45-85 years
Phase:
NA
Brief Summary
Benign prostatic hyperplasia (BPH) is a common problem among aging Caucasian men that produces significant morbidity and hea1th care costs. It is likely that BPH is just as common among Chinese men. D...
Eligibility Criteria
Inclusion
- Chinese ethnicity
- Age between 45-85 years
- Diagnosed to have watchful waiting BPH (Qmax\< 15 ml/sec together with a voided volume of more than 150 mls)
- Not on any concurrent alternative medications for BPH
- Mentally capable to give informed written consent and willing to comply with study requirements
Exclusion
- Prefers to have conventional medical or surgical treatment for BPH
- Concurrent treatment for unstable chronic diseases including unstable angina, poorly controlled DM (HbA1c \>7.5), less than 3 months post-MI or frequent exacerbation of COPD (more than 3x in the last year)
- Known to have prostate cancer or kidney and/or liver failure
- Urinary symptoms due to known causes other than BPH including neurogenic bladder, urinary tract infection, bladder cancer, bladder stone, urethral stricture
- Previous history of prostatic surgery
- Illiterate or having difficulty in filling in a patient diary
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
176 Patients enrolled
Trial Details
Trial ID
NCT00861588
Start Date
February 1 2006
End Date
September 1 2007
Last Update
March 13 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Chinese University of Hong Kong
Hong Kong, Hong Kong